438
Views
1
CrossRef citations to date
0
Altmetric
Short Communications

Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab’)2 to Fab antivenom

, , &
Pages 521-523 | Received 02 Apr 2021, Accepted 24 Aug 2021, Published online: 30 Sep 2021

References

  • Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030–2036.
  • Bush SP, Ruha A-M, Seifert SA, et al. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol. 2015;53(1):37–45.
  • Gerardo CJ, Vissoci JRN, Brown MWJ, et al. Coagulation parameters in copperhead compared to other crotalinae envenomation: secondary analysis of the F(ab’)2 versus Fab antivenom trial. Clin Toxicol. 2017;55(2):109–114.
  • Ruha A-M, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North american snakebite registry. J Med Toxicol. 2017;13(4):309–320.
  • Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with crotalidae polyvalent immune fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med. 2004;43(2):200–206.
  • Gerardo CJ, Quackenbush E, Lewis B, et al. The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: a randomized, double-blind, placebo-controlled, clinical trial. Ann Emerg Med. 2017;70(2):233–244.e3.
  • Dart RC, Hurlbut KM, Garcia R, et al. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med. 1996;27(3):321–326.
  • ANAVIP® crotalidae immune F(ab’)2 (equine) [package insert]. Franklin, TN: Rare Disease Therapeutics, Inc.; 2021.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.